William Mr. Burke Sells 736 Shares of AxoGen (NASDAQ:AXGN) Stock

Key Points

• Director William Mr. Burke sold 736 shares of AxoGen stock at an average price of $18.00, decreasing his ownership by 32.10%.
• AxoGen stock is currently valued at $16.90, with a market cap of $777.57 million and a P/E ratio of -168.98.
• Institutional investors hold 80.29% of AxoGen's shares, with several firms significantly increasing their stakes in the second quarter of the year.

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director William Mr. Burke sold 736 shares of the firm's stock in a transaction on Monday, October 6th. The shares were sold at an average price of $18.00, for a total value of $13,248.00. Following the transaction, the director directly owned 1,557 shares in the company, valued at $28,026. This trade represents a 32.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

AxoGen Price Performance

AxoGen stock traded down $0.26 during trading hours on Tuesday, hitting $16.90. 1,023,288 shares of the company traded hands, compared to its average volume of 842,383. AxoGen, Inc. has a 1-year low of $9.22 and a 1-year high of $21.00. The firm has a market cap of $777.57 million, a P/E ratio of -168.98 and a beta of 1.04. The firm's 50-day simple moving average is $15.77 and its two-hundred day simple moving average is $14.12. The company has a quick ratio of 2.67, a current ratio of 4.14 and a debt-to-equity ratio of 0.59.

Institutional Investors Weigh In On AxoGen

Institutional investors have recently bought and sold shares of the business. Balyasny Asset Management L.P. boosted its holdings in shares of AxoGen by 183.9% during the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider's stock worth $20,953,000 after purchasing an additional 1,250,968 shares during the period. Wasatch Advisors LP raised its holdings in shares of AxoGen by 85.1% during the second quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider's stock worth $15,557,000 after acquiring an additional 659,149 shares in the last quarter. Armistice Capital LLC boosted its position in AxoGen by 106.5% during the second quarter. Armistice Capital LLC now owns 1,111,319 shares of the medical equipment provider's stock valued at $12,058,000 after purchasing an additional 573,041 shares during the last quarter. Invesco Ltd. boosted its position in AxoGen by 2,124.5% during the first quarter. Invesco Ltd. now owns 382,429 shares of the medical equipment provider's stock valued at $7,075,000 after purchasing an additional 365,237 shares during the last quarter. Finally, Squarepoint Ops LLC grew its stake in AxoGen by 259.2% in the second quarter. Squarepoint Ops LLC now owns 483,563 shares of the medical equipment provider's stock valued at $5,247,000 after purchasing an additional 348,950 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on AXGN shares. HC Wainwright started coverage on AxoGen in a report on Tuesday, September 30th. They set a "buy" rating and a $25.00 target price on the stock. Wall Street Zen upgraded shares of AxoGen from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of AxoGen in a report on Saturday, September 27th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $25.75.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.